Brief: BioInvent Posts Positive Early Data From Solid Cancer Trial
20/12/2021 06:41
Dec 20 (Reuters) - BioInvent BINV.ST :
* ANNOUNCED ON FRIDAY POSITIVE EARLY DATA FROM ONGOING
CLINICAL
STUDY OF ITS NOVEL ANTI-FCYRIIB ANTIBODY BI-1206 IN COMBINATION
WITH ANTI-PD-1 THERAPY PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF
PATIENTS WITH SOLID TUMORS
* EARLY OBSERVATIONS ARE THAT BI-1206 MAY STEM AND REVERSE
METASTATIC DISEASE PROGRESSION IN PATIENTS WHO HAVE PREVIOUSLY
PROGRESSED ON PD-1/PDL-1 THERAPIES AND OTHER PRIOR TREATMENTS
* NO MAJOR SAFETY CONCERNS HAVE BEEN NOTED
Source text for Eikon: urn:newsml:reuters.com:*:nMFN6vfsct
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))